Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23

REPLIGEN CORP

2024-Q3 EPS reported $0.15 revenue$466,892,000

GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.
Adjusted gross margin 50.7%; adjusted operating margin 14.9% vs 3.7%.
Full-year 2024 revenue guidance narrowed to $630-$639M (midpoint unchanged).
CDMO revenue and orders each grew ~20% YoY; new modalities record quarterly revenue.
Announced definitive agreement to acquire chromatography firm Tantti Laboratory Inc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.